Go or go go? J&J’s cell therapy heads to the FDA
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.